Literature DB >> 34018720

Changing the Wound: Covalent Immobilization of the Epidermal Growth Factor.

VijayKrishna Raghunathan1,2,3, Shin Ae Park1,4, Nihar M Shah1,5, Christopher M Reilly6, Leandro Teixeira7, Richard Dubielzig7, Yow-Ren Chang1, Monica J Motta1, Michael J Schurr8, Jonathan F McAnulty9, R Rivkah Isseroff10, Nicholas L Abbott11, Christopher J Murphy1,12.   

Abstract

Re-epithelialization of wounds is a critical element of wound closure. Growth factors have been used in combination with conventional wound management to promote closure, but the method of delivery has been limited to the topical application of ointment formulations. Cytoactive factors delivered in this way have short resident times in wounds and have met with limited success. Here, we demonstrate that methods used to covalently immobilize proteins on synthetic materials can be extended to immobilize cytoactive factors such as the epidermal growth factor (EGF) onto the wound beds of genetically diabetic mice that exhibit impaired healing. Full-thickness splinted excisional wounds were created in diabetic (db/db) mice with a well-defined silicone splint to limit wound contracture. Wound surfaces were treated with a reducing agent to expose sulfhydryl groups and subsequently treated with EGF modified with a heterobifunctional crosslinker. This allowed for the covalent immobilization of the EGF to the wound surface. The conjugation chemistry was validated in vitro and in vivo. In a separate group of mice, wounds were topically treated twice daily with soluble EGF. The mice were evaluated over 11 days for wound closure. This covalent immobilization strategy resulted in EGF being retained on the wound surface for 2 days and significantly increased epithelial wound closure by 20% compared to wounds treated with topical EGF or topical vehicle. Covalent immobilization was not only therapeutically effective but also delivered a markedly reduced load of growth factor to the wound surface compared to topical application (when only 180 ng of EGF was immobilized onto the wound surface in comparison with 7200 ng of topically applied EGF over a period of 11 days). No adverse effects were observed in treated wounds. Results obtained provide proof of concept for the effectiveness of covalent immobilization in the treatment of dysregulated wounds. The covalent immobilization of cytoactive factors represents a potentially transformative approach to the management of difficult chronic wounds.

Entities:  

Keywords:  bioconjugation; covalent immobilization; diabetes; epidermal growth factor; wound healing

Mesh:

Substances:

Year:  2021        PMID: 34018720      PMCID: PMC8207651          DOI: 10.1021/acsbiomaterials.1c00192

Source DB:  PubMed          Journal:  ACS Biomater Sci Eng        ISSN: 2373-9878


  63 in total

1.  Outcomes in controlled and comparative studies on non-healing wounds: recommendations to improve the quality of evidence in wound management.

Authors:  F Gottrup; J Apelqvist; P Price
Journal:  J Wound Care       Date:  2010-06       Impact factor: 2.072

2.  Assessment of full-thickness wounds in the genetically diabetic mouse for suitability as a wound healing model.

Authors:  L H Senter; E K Legrand; K E Laemmerhirt; T C Kiorpes
Journal:  Wound Repair Regen       Date:  1995 Jul-Sep       Impact factor: 3.617

3.  Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study.

Authors:  T J Wieman; J M Smiell; Y Su
Journal:  Diabetes Care       Date:  1998-05       Impact factor: 19.112

Review 4.  The FDA and designing clinical trials for chronic cutaneous ulcers.

Authors:  Andrea D Maderal; Alejandra C Vivas; William H Eaglstein; Robert S Kirsner
Journal:  Semin Cell Dev Biol       Date:  2012-10-09       Impact factor: 7.727

5.  Outcomes of conventional wound treatment in a comprehensive wound center.

Authors:  Gabriel Akopian; Susan P Nunnery; Jenny Piangenti; Pam Rankin; Chugo Rinoie; Elizabeth Lee; Magdi Alexander
Journal:  Am Surg       Date:  2006-04       Impact factor: 0.688

6.  Human skin wounds: a major and snowballing threat to public health and the economy.

Authors:  Chandan K Sen; Gayle M Gordillo; Sashwati Roy; Robert Kirsner; Lynn Lambert; Thomas K Hunt; Finn Gottrup; Geoffrey C Gurtner; Michael T Longaker
Journal:  Wound Repair Regen       Date:  2009 Nov-Dec       Impact factor: 3.617

7.  [Combined chronic toxicity/carcinogenicity test of tris(2-chloroethyl)phosphate (TCEP) applied to female mouse skin].

Authors:  K Takada; H Yoshimoto; K Yasuhara; J Momma; Y Aida; M Saito; Y Kurokawa; M Tobe
Journal:  Eisei Shikenjo Hokoku       Date:  1991

8.  Time course study of delayed wound healing in a biofilm-challenged diabetic mouse model.

Authors:  Ge Zhao; Marcia L Usui; Robert A Underwood; Pradeep K Singh; Garth A James; Philip S Stewart; Philip Fleckman; John E Olerud
Journal:  Wound Repair Regen       Date:  2012 May-Jun       Impact factor: 3.617

Review 9.  Growth factors and wound healing: biochemical properties of growth factors and their receptors.

Authors:  N T Bennett; G S Schultz
Journal:  Am J Surg       Date:  1993-06       Impact factor: 2.565

10.  PDGF-BB does not accelerate healing in diabetic mice with splinted skin wounds.

Authors:  Shin Ae Park; Vijay Krishna Raghunathan; Nihar M Shah; Leandro Teixeira; Monica J Motta; Jill Covert; Richard Dubielzig; Michael Schurr; Roslyn Rivkah Isseroff; Nicholas L Abbott; Jonathan McAnulty; Christopher J Murphy
Journal:  PLoS One       Date:  2014-08-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.